Introduction {#Sec1}
============

In the early 2000\'s, two randomized controlled trials have shown that non-invasive ventilation (NIV) could decrease mortality of immunocompromised patients admitted to ICU for acute respiratory failure (ARF) as compared to standard oxygen therapy (O~2~) \[[@CR1], [@CR2]\]. However, the benefits of NIV in immunocompetent patients with ARF failure are debated. High flow nasal cannula oxygen therapy (High-Flow Oxygen) may offer an alternative in hypoxemic patients. We recently found in a randomized controlled trial including 310 patients with ARF that High-Flow Oxygen decreased mortality as compared to NIV \[[@CR3]\]. Immunocompromised patients could be also included in this study, except those with profound neutropenia. Therefore, we assessed the benefits of High-Flow Oxygen or NIV in this subgroup of patients.

Objectives {#Sec2}
==========

To compare intubation and mortality rates in the subset of immunocompromised patients admitted to ICU for ARF.

Methods {#Sec3}
=======

We performed a subgroup analysis of the FLORALI study. This study included all patients with non-hypercapnic (PaCO~2~ ≤ 45 mm Hg) ARF excluding patients with cardiogenic pulmonary edema and those with underlying chronic lung disease. Patients were assigned to three groups according to treatment: High-Flow Oxygen, O~2~ or NIV. The primary outcome was the intubation rate and secondary outcome included 90-day mortality. We focused on the subset of immunocompromised patients included in this study, knowing that patients with profound neutropenia were excluded.

Results {#Sec4}
=======

Among the 310 patients with ARF, 82 (26%) were immunocompromised including 26 patients in the High-Flow Oxygen group, 30 in the O~2~ group, and 26 in the NIV group. Intubation rates were 31%, 43% and 55% in the High-Flow Oxygen, O~2~ and NIV groups, respectively (p = 0.04). The 90-day mortality rates were 15%, 27% and 46% in the High-Flow Oxygen, O~2~ and NIV groups (p = 0.046). Ventilator-free days at day 28 were 26 ± 6, 23 ± 10 and 14 ± 13 days in the High-Flow Oxygen, O~2~ and NIV groups, respectively (p \< 0.0001).

Conclusions {#Sec5}
===========

In immunocompromised patients admitted to ICU for acute hypoxemic respiratory failure, High-Flow Oxygen was associated with lower intubation and mortality rates, and a reduced duration of invasive mechanical ventilation as compared to O~2~ or NIV.
